Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*
By Angel López, J. Lorente, Jay S. Steingrub, J. Bakker, A. Mcluckie, S. Willatts, M. Brockway, A. Anzueto, L. Holzapfel, D. Breen and 7 more. Critical Care Medicine, 2004
893 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Immunology
View Paper: https://www.semanticscholar.org/paper/d56e86fd12b878eb093495ee8e259fecc6d069a0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Immunology
Citations in the corpus
- Inducible Nitric Oxide Synthase: Regulation, Structure, and Inhibition (2019, background): “Although some beneficial effects have been shown, nonselective iNOS inhibition (such as with 2) can actually increase cardiac dysfunction and mortality in septic shock patients.(185) It is proposed that eNOS could have some protective role in sepsis (as has been demonstrated in murine eNOS overexpre”
- The discovery of nitric oxide and its role in vascular biology (2006, result): “This led to the testing of this compound in a clinical trial in septic shock (Lopez et al., 2004).”
- The immunology of sepsis (2008, background): “A number of randomized, controlled clinical trials of immunomodulators targeting the inflammatory axis in severe sepsis were undertaken in the 1990s, yet failed to show any benefit; indeed, in some cases, the trial drugs led to increased mortality [61,62].”
- American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock (2017, background): “Studies have shown an increased mortality with nonselective NO synthase inhibitors suggesting that increasing blood pressure through excessive vasoconstriction can have adverse effects (261).”